EUROPEAN HEALTH INFORMATION GATEWAY
  • Number of all cases cancer at year's end, males (Line chart)
  • Number of all cases cancer at year's end, males (Bar chart)
Data set notes
European Health for All database (WHO)

The following abbreviations are used in the indicator titles:
•    SDR: age-standardized death rates (see HFA-DB user manual/Technical notes, page 13, for details)
•    FTE: full-time equivalent
•    PP: physical persons
•    PPP$: purchasing power parities expressed in US $, an internationally comparable scale reflecting the relative domestic purchasing powers of currencies.

Indicator notes
Number of all cases cancer at year's end, males
Indicator code: E045601.M This indicator shares the definition with the parent indicator \"Number of all cases of cancer at year's end\".

Cumulative number of cancer patients (old and new cases). Data from the cancer register whenever available or from the existing routine reporting system of health establishments._
Country notes
Albania
Ministry of Health.
Armenia
Source of data: National Health Information Analytic Center, Ministry of Health of the Republic of
Armenia http://moh.am/?section=static_pages/index&id=625&subID=824,29.
Data collected annually, reference period: 31 December.
Austria
Source: Statistics Austria, Austrian Cancer Registry.
Belgium
Source 2010:
http://www.kankerregister.be/media/docs/publications/PrevalenceinBelgium2010_e-book.pdf. This report
estimates the 1, 5, 10, 15 and 20-year prevalence with an index date of 31st December 2010. For
consistency with the 2013 data, the 5-year prevalence estimates are used.
Source 2013:
http://www.kankerregister.org/media/docs/publications/BCR_publicatieCancerBurden2015.pdf. Five-year
prevalence data were estimated with an index date of 31st December 2013, representing people living
in Belgium who were diagnosed with at least one invasive malignancy in the period from 1st January
2009 to 31st December 2013 and who were still alive at the end of 2013 (index date). Persons with
more than one malignancy were included as prevalent cases in each cancer type, but were counted only
once in analysis regrouping multiple tumour sites.
Bosnia and Herzegovina
Public Health Institute - Department of health statistics and informatics - Annual ambulants report.
Public Health Institute of Federation of B&H; Department for Health Statistics and Informatics
Public Health Institute of Republic of Srpska. Department for social medicine with health
organization and health economics. Law on Health Evidence and Statistical Research in Health. Annual
report of health facilities
Department for Health of Brcko District
Croatia
Without skin cancer.
Cyprus
No data are available
Czechia
Cumulative number of notified cases (old and new cases) in living persons at the end of the given
calendar year. Source: Czech National Cancer Registry.
Denmark
Source: The Cancer Registry, The Danish Health Data Authority..
http://www.ssi.dk/Sundhedsdataogit/Registre/Cancerregisteret.aspx
From 1998 and onwards basocellular skin cancer (C44) is no longer included in the definition, which
explains the data break between 1997-1998.
Estonia
Source: Estonian Cancer Registry, National Institute for Health Development.
Data updated in April 2016.
Finland
Source: Finnish Cancer Registry, Cancer Society of Finland based on agreement with THL (National
Institute for Health and Welfare).
Source: Cancer Register, THL (National Institute for Health and Welfare) / Cancer Organizations.
France
Source: Instititut national du cancer: http://www.e-cancer.fr/
Deviation from the definition: number of persons alive diagnosed with cancer in the last five years.
Georgia
Source: National Centre for Disease Control and Public Health of Georgia (NCDC)
(http://www.ncdc.ge).
Due to reform in 2011, the data may show inconsistency.
Germany
Source: Robert Koch-Institute - German Centre for Cancer Registry Data (ZfKD)
http://www.krebsdaten.de or http://www.rki.de
Coverage: Data contain the estimated number of persons living on a specific date (in this case
December, 31 2012) who were newly diagnosed with cancer within the previous five years (in this case
between 2008 and 2012).
Estimation method: The population-based cancer registries in each German federal state transfer data
to the German Centre for Cancer Registry Data (ZfKD), as required by the Federal Cancer Registry
Data Act (Bundeskrebsregisterdatengesetz). These data are combined, quality-checked, analysed and
evaluated.
At the moment reliable data on cancer incidence and survival are not available for all federal
states. Therefore, the ZfKD estimates new diagnosis, prevalence and survival rates for Germany in
addition to estimating the completeness of data capture in the individual registries. The basic
principle is that the data are first checked for registration completeness and, upon meeting
pre-defined criteria, are then used for the calculation of the various statistics.
The value of population-based cancer data vitally depends on the completeness of the capture of all
newly diagnosed cancer cases. Since 2009 in all federal states there has been comprehensive
geographical epidemiological cancer registration and great advances have been achieved. But the
situation in the individual states is very heterogeneous: continuous, state-wide registration was
commenced between 1967 (Saarland) and 2009 (Baden-Wurttemberg). The ZfKD consequently regularly
estimates the degree of completeness for the population-based cancer registries.
The basis for this evaluation is the ratio of incidence to mortality (M/I-Index), an internationally
commonly used indicator. It is assumed here that diagnosis and survival prospects of cancer patients
within Germany do not differ fundamentally and that regionally differing cancer risks can thus be
approximated by official cause of death statistics. Using the M/I-Index of a reference registry that
has been assessed as being complete along with the cancer mortality at a region whose completeness
is to be assessed, it is possible to estimate the expected cancer incidence in that region and
compare it with the number of cases actually registered.
According to the current evaluation, for the year 2012, twelve federal states have already reached
an estimated completeness level of at least 90%, seven federal states have reached over 95%
completeness.
The prevalence was calculated according to Piasini?s method using the estimated incidence rates for
Germany and the absolute survival rates (according to age, gender, localisation and calendar year)
calculated using period analysis.
Absolute survival rates represent the percentage of patients that are still alive at a particular
time after their diagnosis. An absolute 5-year survival of 80%, for example, means that 80 out of
100 persons diagnosed with a particular form of cancer have survived the first five years after
diagnosis.
In order to estimate survival prospects that are as most up-to-date as possible, the so-called
?Period Analyisis? according to Brenner was used. This takes into account all information pertaining
to the survival of persons alive during a particular period of time (e.g. 20011-2012). Included in
the calculation for the period 2011 to 2012, therefore, are all people who were diagnosed between
2008 and 2012 and who were still alive at the end of 2012. The result can be interpreted as an
estimate of the survival rates for patients diagnosed between 2011 and 2012, whose 5-year survival
naturally cannot be directly determined until the end of 2017 at the earliest. Assuming a continual
improvement in the survival rate over time, a slight underestimation of the true survival prospects
should be assumed.
Because the accuracy of survival analyses depends very much on the quality of the underlying data,
registries were include
Greece
Since 1982, the total number of discharged patients that were hospitalized in public hospitals and
private clinics with cancer.
Iceland
Source: Icelandic Cancer Registry.
A cumulative number of all diagnosed cases from 1955. Number represents individuals who are still
alive at the end of a given year. All cancers (in different organs) in each individual are included
(not just the first cancer).
Ireland
Source: National Cancer Registry. Complete prevalence unavailable but period prevalence (1994-2011,
all invasive cancers excluding non-melanoma skin cancer) is shown. Complete prevalence data
(prevalence defined as the number of patients still alive in the population that ever had a
diagnosis of cancer) cannot provided due to lack of information on patients diagnosed before 1994.
Israel
Number of people, living, diagnosed with cancer within the last 5 years.
Source: Israel Cancer Registry, Ministry of Health.
Italy
It is estimated by means of specific epidemiological studies. Source: Istituto Superiore di Sanita,
Centro Nazionale di Epidemiologia Sorveglianza e Prevenzione della Salute (ISS, CNESPS). Estimates
were obtained with the MIAMOD methodology using cancer-specific mortality 1970-2002 (Official
National Statistics - ISTAT) and survival of patients diagnosed in 1985-2002 (Italian Network of
Cancer Registries - AIRTUM). The MIAMOD method was applied to obtain forecasts from 2003 onwards .
Cancer-specific estimates were obtained separately by sex for the 20 Italian regions. National
estimates were obtained by summing up the regional estimates. All prevalent cases of cancer
(including all patients surviving after a cancer diagnosis) were derived by summing up the
estimated number of prevalent cases for cancers of colon-rectum, lung, stomach, prostate (males) or
breast (females), and for all other cancers combined. All estimates are referred to age group 0-99
years.
Latvia
Source of data: the Register of Patients with Particular Diseases
Break in time series: Up to 2002 the data source was the annual statistical report. Starting from
2003 the data source is the Register of Patients with Particular Diseases.
Lithuania
Source: National Cancer Register.
Luxembourg
Data are not available.
Malta
Data are not available.
Montenegro
Data are not available.
Netherlands
RIVM (The National Institute for Public Health and the Environment), based on LINH (Netherlands
Information Network of General Practice). The LINH is based on 5 GP registers.
Poland
Data are not available.
Portugal
Source of data: Ministry of Health - National Health Institute and National Institute for
Statistics, National Health Survey 2005-2006 Coverage: National
Romania
Source: The number of new cases of cancer is reported by each district?s oncological cabinet to
National Center for Statistics and Informatics in Public Health.
Break in time series:
2014: since year 2014, data from private sector included.
Serbia
No data are available.
Slovenia
Source of data: Cancer Registry of Republic of Slovenia, Institute of Oncology Ljubljana, March
2016.
Methodology (definition): Lifetime prevalence is defined as the number of all persons ever diagnosed
with cancer and being alive at specific time date (usually the last day of calendar year). If the
person is diagnosed with more than one cancer in his/her lifetime, we count each cancer diagnose in
lifetime prevalence, but in prevalence of all cancer sites together we count each person only once..
Sweden
Source of data: National Board of Health and Welfare (NBHW)
The Swedish Cancer Register (NBHW)
Online Database: http://www.socialstyrelsen.se/statistics/statisticaldatabase/cancer
Switzerland
Only hospital discharge data available yet. The series have been erased as the information is not
sufficient.
Turkey
No data are available.
Turkmenistan
Source of data: Administrative medical statistics, forms: 7 ?Report on the incidence of and patients
with cancer?, 5 ?Report on morbidity?, 025-2/y ?Statistical card?.
Ukraine
November 2002: Source: Centre of Health Statistics, Ministry of Health.
United Kingdom
Data are not available.